Extended	O
use	O
of	O
Prostate	B:C4084801
Health	I:C4084801
Index	I:C4084801
and	O
percentage	O
of	O
[	O
-	I:C3710767
2	I:C3710767
]	I:C3710767
pro-	I:C3710767
prostate	I:C3710767
-	I:C3710767
specific	I:C3710767
antigen	I:C3710767
in	O
Chinese	O
men	O
with	O
prostate	O
specific	I:C0138741
antigen	I:C0138741
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
.	O

Extended	O
use	O
of	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
and	O
percentage	O
of	O
[	B:C3710767
-	I:C3710767
2	I:C3710767
]	I:C3710767
pro-	I:C3710767
prostate	I:C3710767
-	I:C3710767
specific	I:C3710767
antigen	I:C3710767
in	O
Chinese	O
men	O
with	O
prostate	O
specific	I:C0138741
antigen	I:C0138741
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
.	O

Extended	O
use	O
of	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
and	O
percentage	O
of	O
[	O
-	I:C3710767
2	I:C3710767
]	I:C3710767
pro-	I:C3710767
prostate	I:C3710767
-	I:C3710767
specific	I:C3710767
antigen	I:C3710767
in	O
Chinese	B:C0152035
men	O
with	O
prostate	O
specific	I:C0138741
antigen	I:C0138741
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
.	O

Extended	O
use	O
of	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
and	O
percentage	O
of	O
[	O
-	I:C3710767
2	I:C3710767
]	I:C3710767
pro-	I:C3710767
prostate	I:C3710767
-	I:C3710767
specific	I:C3710767
antigen	I:C3710767
in	O
Chinese	O
men	B:C0025266
with	O
prostate	O
specific	I:C0138741
antigen	I:C0138741
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
.	O

Extended	O
use	O
of	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
and	O
percentage	O
of	O
[	O
-	I:C3710767
2	I:C3710767
]	I:C3710767
pro-	I:C3710767
prostate	I:C3710767
-	I:C3710767
specific	I:C3710767
antigen	I:C3710767
in	O
Chinese	O
men	O
with	O
prostate	B:C0138741
specific	I:C0138741
antigen	I:C0138741
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
.	O

Extended	O
use	O
of	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
and	O
percentage	O
of	O
[	O
-	I:C3710767
2	I:C3710767
]	I:C3710767
pro-	I:C3710767
prostate	I:C3710767
-	I:C3710767
specific	I:C3710767
antigen	I:C3710767
in	O
Chinese	O
men	O
with	O
prostate	O
specific	I:C0138741
antigen	I:C0138741
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	B:C1384593
rectal	I:C1384593
examination	I:C1384593
.	O

We	O
investigated	O
the	O
extended	O
use	O
of	O
Prostate	B:C4084801
Health	I:C4084801
Index	I:C4084801
(	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
)	O
and	O
percentage	O
of	O
[	O
-	I:C3710767
2	I:C3710767
]	I:C3710767
pro-	I:C3710767
prostate	I:C3710767
-	I:C3710767
specific	I:C3710767
antigen	I:C3710767
(	O
%	O
p2PSA	I:C3710767
)	O
in	O
Chinese	O
men	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
10	O
-	O
20	O
ng/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
(	O
digital	O
rectal	I:C1384593
examination	I:C1384593
)	O
.	O

We	O
investigated	O
the	O
extended	O
use	O
of	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
(	O
Prostate	B:C4084801
Health	I:C4084801
Index	I:C4084801
)	O
and	O
percentage	O
of	O
[	O
-	I:C3710767
2	I:C3710767
]	I:C3710767
pro-	I:C3710767
prostate	I:C3710767
-	I:C3710767
specific	I:C3710767
antigen	I:C3710767
(	O
%	O
p2PSA	I:C3710767
)	O
in	O
Chinese	O
men	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
10	O
-	O
20	O
ng/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
(	O
digital	O
rectal	I:C1384593
examination	I:C1384593
)	O
.	O

We	O
investigated	O
the	O
extended	O
use	O
of	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
(	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
)	O
and	O
percentage	O
of	O
[	B:C3710767
-	I:C3710767
2	I:C3710767
]	I:C3710767
pro-	I:C3710767
prostate	I:C3710767
-	I:C3710767
specific	I:C3710767
antigen	I:C3710767
(	O
%	O
p2PSA	I:C3710767
)	O
in	O
Chinese	O
men	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
10	O
-	O
20	O
ng/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
(	O
digital	O
rectal	I:C1384593
examination	I:C1384593
)	O
.	O

We	O
investigated	O
the	O
extended	O
use	O
of	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
(	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
)	O
and	O
percentage	O
of	O
[	O
-	I:C3710767
2	I:C3710767
]	I:C3710767
pro-	I:C3710767
prostate	I:C3710767
-	I:C3710767
specific	I:C3710767
antigen	I:C3710767
(	O
%	B:C3710767
p2PSA	I:C3710767
)	O
in	O
Chinese	O
men	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
10	O
-	O
20	O
ng/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
(	O
digital	O
rectal	I:C1384593
examination	I:C1384593
)	O
.	O

We	O
investigated	O
the	O
extended	O
use	O
of	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
(	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
)	O
and	O
percentage	O
of	O
[	O
-	I:C3710767
2	I:C3710767
]	I:C3710767
pro-	I:C3710767
prostate	I:C3710767
-	I:C3710767
specific	I:C3710767
antigen	I:C3710767
(	O
%	O
p2PSA	I:C3710767
)	O
in	O
Chinese	B:C0152035
men	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
10	O
-	O
20	O
ng/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
(	O
digital	O
rectal	I:C1384593
examination	I:C1384593
)	O
.	O

We	O
investigated	O
the	O
extended	O
use	O
of	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
(	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
)	O
and	O
percentage	O
of	O
[	O
-	I:C3710767
2	I:C3710767
]	I:C3710767
pro-	I:C3710767
prostate	I:C3710767
-	I:C3710767
specific	I:C3710767
antigen	I:C3710767
(	O
%	O
p2PSA	I:C3710767
)	O
in	O
Chinese	O
men	B:C0025266
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
10	O
-	O
20	O
ng/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
(	O
digital	O
rectal	I:C1384593
examination	I:C1384593
)	O
.	O

We	O
investigated	O
the	O
extended	O
use	O
of	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
(	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
)	O
and	O
percentage	O
of	O
[	O
-	I:C3710767
2	I:C3710767
]	I:C3710767
pro-	I:C3710767
prostate	I:C3710767
-	I:C3710767
specific	I:C3710767
antigen	I:C3710767
(	O
%	O
p2PSA	I:C3710767
)	O
in	O
Chinese	O
men	O
with	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
10	O
-	O
20	O
ng/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
(	O
digital	O
rectal	I:C1384593
examination	I:C1384593
)	O
.	O

We	O
investigated	O
the	O
extended	O
use	O
of	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
(	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
)	O
and	O
percentage	O
of	O
[	O
-	I:C3710767
2	I:C3710767
]	I:C3710767
pro-	I:C3710767
prostate	I:C3710767
-	I:C3710767
specific	I:C3710767
antigen	I:C3710767
(	O
%	O
p2PSA	I:C3710767
)	O
in	O
Chinese	O
men	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
10	O
-	O
20	O
ng/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
(	O
digital	O
rectal	I:C1384593
examination	I:C1384593
)	O
.	O

We	O
investigated	O
the	O
extended	O
use	O
of	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
(	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
)	O
and	O
percentage	O
of	O
[	O
-	I:C3710767
2	I:C3710767
]	I:C3710767
pro-	I:C3710767
prostate	I:C3710767
-	I:C3710767
specific	I:C3710767
antigen	I:C3710767
(	O
%	O
p2PSA	I:C3710767
)	O
in	O
Chinese	O
men	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
10	O
-	O
20	O
ng/	O
mL	O
and	O
normal	O
digital	B:C1384593
rectal	I:C1384593
examination	I:C1384593
(	O
digital	O
rectal	I:C1384593
examination	I:C1384593
)	O
.	O

We	O
investigated	O
the	O
extended	O
use	O
of	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
(	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
)	O
and	O
percentage	O
of	O
[	O
-	I:C3710767
2	I:C3710767
]	I:C3710767
pro-	I:C3710767
prostate	I:C3710767
-	I:C3710767
specific	I:C3710767
antigen	I:C3710767
(	O
%	O
p2PSA	I:C3710767
)	O
in	O
Chinese	O
men	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
10	O
-	O
20	O
ng/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
(	O
digital	B:C1384593
rectal	I:C1384593
examination	I:C1384593
)	O
.	O

All	O
consecutive	O
Chinese	B:C0152035
men	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
who	O
agreed	O
for	O
transrectal	O
ultrasound	I:C0373345
(	O
transrectal	O
ultrasound	I:C0373345
)	O
-	O
guided	O
10	O
-	O
core	O
prostate	O
biopsy	I:C0194804
were	O
recruited	O
.	O

All	O
consecutive	O
Chinese	O
men	B:C0025266
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
who	O
agreed	O
for	O
transrectal	O
ultrasound	I:C0373345
(	O
transrectal	O
ultrasound	I:C0373345
)	O
-	O
guided	O
10	O
-	O
core	O
prostate	O
biopsy	I:C0194804
were	O
recruited	O
.	O

All	O
consecutive	O
Chinese	O
men	O
with	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
who	O
agreed	O
for	O
transrectal	O
ultrasound	I:C0373345
(	O
transrectal	O
ultrasound	I:C0373345
)	O
-	O
guided	O
10	O
-	O
core	O
prostate	O
biopsy	I:C0194804
were	O
recruited	O
.	O

All	O
consecutive	O
Chinese	O
men	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	B:C1384593
rectal	I:C1384593
examination	I:C1384593
who	O
agreed	O
for	O
transrectal	O
ultrasound	I:C0373345
(	O
transrectal	O
ultrasound	I:C0373345
)	O
-	O
guided	O
10	O
-	O
core	O
prostate	O
biopsy	I:C0194804
were	O
recruited	O
.	O

All	O
consecutive	O
Chinese	O
men	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
who	O
agreed	O
for	O
transrectal	B:C0373345
ultrasound	I:C0373345
(	O
transrectal	O
ultrasound	I:C0373345
)	O
-	O
guided	O
10	O
-	O
core	O
prostate	O
biopsy	I:C0194804
were	O
recruited	O
.	O

All	O
consecutive	O
Chinese	O
men	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
who	O
agreed	O
for	O
transrectal	O
ultrasound	I:C0373345
(	O
transrectal	B:C0373345
ultrasound	I:C0373345
)	O
-	O
guided	O
10	O
-	O
core	O
prostate	O
biopsy	I:C0194804
were	O
recruited	O
.	O

All	O
consecutive	O
Chinese	O
men	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
who	O
agreed	O
for	O
transrectal	O
ultrasound	I:C0373345
(	O
transrectal	O
ultrasound	I:C0373345
)	O
-	O
guided	O
10	O
-	O
core	O
prostate	B:C0194804
biopsy	I:C0194804
were	O
recruited	O
.	O

Blood	B:C0178913
samples	I:C0178913
were	O
taken	O
immediately	O
before	O
transrectal	O
ultrasound	I:C0373345
-	O
guided	O
prostate	O
biopsy	I:C0194804
.	O

Blood	O
samples	I:C0178913
were	O
taken	O
immediately	O
before	O
transrectal	B:C0373345
ultrasound	I:C0373345
-	O
guided	O
prostate	O
biopsy	I:C0194804
.	O

Blood	O
samples	I:C0178913
were	O
taken	O
immediately	O
before	O
transrectal	O
ultrasound	I:C0373345
-	O
guided	O
prostate	B:C0194804
biopsy	I:C0194804
.	O

The	O
performances	O
of	O
total	B:C2986589
PSA	I:C2986589
(	O
total	O
PSA	I:C2986589
)	O
,	O
%	O
free	O
-	O
to	O
-	O
total	O
PSA	O
(	O
%	O
fPSA	O
)	O
,	O
%p2PSA	O
,	O
and	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
were	O
compared	O
using	O
logistic	O
regression	I:C0206031
,	O
receiver	O
operating	O
characteristic	O
,	O
and	O
decision	O
curve	I:C0936012
analyses	I:C0936012
(	O
decision	O
curve	I:C0936012
analyses	I:C0936012
)	O
.	O

The	O
performances	O
of	O
total	O
PSA	I:C2986589
(	O
total	B:C2986589
PSA	I:C2986589
)	O
,	O
%	O
free	O
-	O
to	O
-	O
total	O
PSA	O
(	O
%	O
fPSA	O
)	O
,	O
%p2PSA	O
,	O
and	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
were	O
compared	O
using	O
logistic	O
regression	I:C0206031
,	O
receiver	O
operating	O
characteristic	O
,	O
and	O
decision	O
curve	I:C0936012
analyses	I:C0936012
(	O
decision	O
curve	I:C0936012
analyses	I:C0936012
)	O
.	O

The	O
performances	O
of	O
total	O
PSA	I:C2986589
(	O
total	O
PSA	I:C2986589
)	O
,	O
%	O
free	O
-	O
to	O
-	O
total	O
PSA	O
(	O
%	O
fPSA	O
)	O
,	O
%p2PSA	B:C3710767
,	O
and	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
were	O
compared	O
using	O
logistic	O
regression	I:C0206031
,	O
receiver	O
operating	O
characteristic	O
,	O
and	O
decision	O
curve	I:C0936012
analyses	I:C0936012
(	O
decision	O
curve	I:C0936012
analyses	I:C0936012
)	O
.	O

The	O
performances	O
of	O
total	O
PSA	I:C2986589
(	O
total	O
PSA	I:C2986589
)	O
,	O
%	O
free	O
-	O
to	O
-	O
total	O
PSA	O
(	O
%	O
fPSA	O
)	O
,	O
%p2PSA	O
,	O
and	O
Prostate	B:C4084801
Health	I:C4084801
Index	I:C4084801
were	O
compared	O
using	O
logistic	O
regression	I:C0206031
,	O
receiver	O
operating	O
characteristic	O
,	O
and	O
decision	O
curve	I:C0936012
analyses	I:C0936012
(	O
decision	O
curve	I:C0936012
analyses	I:C0936012
)	O
.	O

The	O
performances	O
of	O
total	O
PSA	I:C2986589
(	O
total	O
PSA	I:C2986589
)	O
,	O
%	O
free	O
-	O
to	O
-	O
total	O
PSA	O
(	O
%	O
fPSA	O
)	O
,	O
%p2PSA	O
,	O
and	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
were	O
compared	O
using	O
logistic	B:C0206031
regression	I:C0206031
,	O
receiver	O
operating	O
characteristic	O
,	O
and	O
decision	O
curve	I:C0936012
analyses	I:C0936012
(	O
decision	O
curve	I:C0936012
analyses	I:C0936012
)	O
.	O

The	O
performances	O
of	O
total	O
PSA	I:C2986589
(	O
total	O
PSA	I:C2986589
)	O
,	O
%	O
free	O
-	O
to	O
-	O
total	O
PSA	O
(	O
%	O
fPSA	O
)	O
,	O
%p2PSA	O
,	O
and	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
were	O
compared	O
using	O
logistic	O
regression	I:C0206031
,	O
receiver	O
operating	O
characteristic	O
,	O
and	O
decision	B:C0936012
curve	I:C0936012
analyses	I:C0936012
(	O
decision	O
curve	I:C0936012
analyses	I:C0936012
)	O
.	O

The	O
performances	O
of	O
total	O
PSA	I:C2986589
(	O
total	O
PSA	I:C2986589
)	O
,	O
%	O
free	O
-	O
to	O
-	O
total	O
PSA	O
(	O
%	O
fPSA	O
)	O
,	O
%p2PSA	O
,	O
and	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
were	O
compared	O
using	O
logistic	O
regression	I:C0206031
,	O
receiver	O
operating	O
characteristic	O
,	O
and	O
decision	O
curve	I:C0936012
analyses	I:C0936012
(	O
decision	B:C0936012
curve	I:C0936012
analyses	I:C0936012
)	O
.	O

From	O
2008	O
to	O
2015	O
,	O
312	O
consecutive	O
Chinese	B:C0152035
men	O
were	O
included	O
.	O

From	O
2008	O
to	O
2015	O
,	O
312	O
consecutive	O
Chinese	O
men	B:C0025266
were	O
included	O
.	O

Among	O
them	O
,	O
53	O
out	O
of	O
312	O
(	O
17.0	O
%	O
)	O
men	B:C0025266
were	O
diagnosed	O
to	O
have	O
prostate	O
cancer	I:C0376358
on	O
biopsy	O
.	O

Among	O
them	O
,	O
53	O
out	O
of	O
312	O
(	O
17.0	O
%	O
)	O
men	O
were	O
diagnosed	B:C0011900
to	O
have	O
prostate	O
cancer	I:C0376358
on	O
biopsy	O
.	O

Among	O
them	O
,	O
53	O
out	O
of	O
312	O
(	O
17.0	O
%	O
)	O
men	O
were	O
diagnosed	O
to	O
have	O
prostate	B:C0376358
cancer	I:C0376358
on	O
biopsy	O
.	O

Among	O
them	O
,	O
53	O
out	O
of	O
312	O
(	O
17.0	O
%	O
)	O
men	O
were	O
diagnosed	O
to	O
have	O
prostate	O
cancer	I:C0376358
on	O
biopsy	B:C0005558
.	O

The	O
proportions	O
of	O
men	B:C0025266
with	O
positive	O
biopsies	I:C1514241
were	O
6.7	O
%	O
in	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
<	O
35	O
,	O
22.8	O
%	O
in	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
35	O
-	O
55	O
,	O
and	O
54.5	O
%	O
in	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
>	O
55	O
(	O
chi-square	O
test	I:C0008041
,	O
p<0.001	O
)	O
.	O

The	O
proportions	O
of	O
men	O
with	O
positive	B:C1514241
biopsies	I:C1514241
were	O
6.7	O
%	O
in	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
<	O
35	O
,	O
22.8	O
%	O
in	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
35	O
-	O
55	O
,	O
and	O
54.5	O
%	O
in	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
>	O
55	O
(	O
chi-square	O
test	I:C0008041
,	O
p<0.001	O
)	O
.	O

The	O
proportions	O
of	O
men	O
with	O
positive	O
biopsies	I:C1514241
were	O
6.7	O
%	O
in	O
Prostate	B:C4084801
Health	I:C4084801
Index	I:C4084801
<	O
35	O
,	O
22.8	O
%	O
in	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
35	O
-	O
55	O
,	O
and	O
54.5	O
%	O
in	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
>	O
55	O
(	O
chi-square	O
test	I:C0008041
,	O
p<0.001	O
)	O
.	O

The	O
proportions	O
of	O
men	O
with	O
positive	O
biopsies	I:C1514241
were	O
6.7	O
%	O
in	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
<	O
35	O
,	O
22.8	O
%	O
in	O
Prostate	B:C4084801
Health	I:C4084801
Index	I:C4084801
35	O
-	O
55	O
,	O
and	O
54.5	O
%	O
in	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
>	O
55	O
(	O
chi-square	O
test	I:C0008041
,	O
p<0.001	O
)	O
.	O

The	O
proportions	O
of	O
men	O
with	O
positive	O
biopsies	I:C1514241
were	O
6.7	O
%	O
in	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
<	O
35	O
,	O
22.8	O
%	O
in	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
35	O
-	O
55	O
,	O
and	O
54.5	O
%	O
in	O
Prostate	B:C4084801
Health	I:C4084801
Index	I:C4084801
>	O
55	O
(	O
chi-square	O
test	I:C0008041
,	O
p<0.001	O
)	O
.	O

The	O
proportions	O
of	O
men	O
with	O
positive	O
biopsies	I:C1514241
were	O
6.7	O
%	O
in	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
<	O
35	O
,	O
22.8	O
%	O
in	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
35	O
-	O
55	O
,	O
and	O
54.5	O
%	O
in	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
>	O
55	O
(	O
chi-square	B:C0008041
test	I:C0008041
,	O
p<0.001	O
)	O
.	O

The	O
area	O
under	O
curves	O
(	O
AUC	O
)	O
of	O
the	O
base	B:C3161035
model	I:C3161035
including	O
age	O
,	O
total	O
PSA	I:C2986589
and	O
status	O
of	O
initial	O
/	O
repeated	O
biopsy	O
was	O
0.64	O
.	O

The	O
area	O
under	O
curves	O
(	O
AUC	O
)	O
of	O
the	O
base	O
model	I:C3161035
including	O
age	O
,	O
total	B:C2986589
PSA	I:C2986589
and	O
status	O
of	O
initial	O
/	O
repeated	O
biopsy	O
was	O
0.64	O
.	O

The	O
area	O
under	O
curves	O
(	O
AUC	O
)	O
of	O
the	O
base	O
model	I:C3161035
including	O
age	O
,	O
total	O
PSA	I:C2986589
and	O
status	O
of	O
initial	O
/	O
repeated	O
biopsy	B:C0005558
was	O
0.64	O
.	O

Adding	O
%	B:C3710767
p2PSA	I:C3710767
and	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
to	O
the	O
base	O
model	I:C3161035
improved	O
the	O
AUC	O
to	O
0.79	O
(	O
p<0.001	O
)	O
and	O
0.78	O
(	O
p<0.001	O
)	O
,	O
respectively	O
,	O
and	O
provided	O
net	O
clinical	O
benefit	O
in	O
decision	O
curve	I:C0936012
analyses	I:C0936012
.	O

Adding	O
%	O
p2PSA	I:C3710767
and	O
Prostate	B:C4084801
Health	I:C4084801
Index	I:C4084801
to	O
the	O
base	O
model	I:C3161035
improved	O
the	O
AUC	O
to	O
0.79	O
(	O
p<0.001	O
)	O
and	O
0.78	O
(	O
p<0.001	O
)	O
,	O
respectively	O
,	O
and	O
provided	O
net	O
clinical	O
benefit	O
in	O
decision	O
curve	I:C0936012
analyses	I:C0936012
.	O

Adding	O
%	O
p2PSA	I:C3710767
and	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
to	O
the	O
base	B:C3161035
model	I:C3161035
improved	O
the	O
AUC	O
to	O
0.79	O
(	O
p<0.001	O
)	O
and	O
0.78	O
(	O
p<0.001	O
)	O
,	O
respectively	O
,	O
and	O
provided	O
net	O
clinical	O
benefit	O
in	O
decision	O
curve	I:C0936012
analyses	I:C0936012
.	O

Adding	O
%	O
p2PSA	I:C3710767
and	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
to	O
the	O
base	O
model	I:C3161035
improved	B:C0184511
the	O
AUC	O
to	O
0.79	O
(	O
p<0.001	O
)	O
and	O
0.78	O
(	O
p<0.001	O
)	O
,	O
respectively	O
,	O
and	O
provided	O
net	O
clinical	O
benefit	O
in	O
decision	O
curve	I:C0936012
analyses	I:C0936012
.	O

Adding	O
%	O
p2PSA	I:C3710767
and	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
to	O
the	O
base	O
model	I:C3161035
improved	O
the	O
AUC	O
to	O
0.79	O
(	O
p<0.001	O
)	O
and	O
0.78	O
(	O
p<0.001	O
)	O
,	O
respectively	O
,	O
and	O
provided	O
net	O
clinical	O
benefit	O
in	O
decision	B:C0936012
curve	I:C0936012
analyses	I:C0936012
.	O

The	O
positive	B:C1514241
biopsy	I:C1514241
rates	O
of	O
Gleason	O
7	I:C0332326
or	I:C0332326
above	I:C0332326
prostate	O
cancers	I:C0376358
were	O
2.2	O
%	O
for	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
<	O
35	O
,	O
7.9	O
%	O
for	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
35	O
-	O
55	O
,	O
and	O
36.4	O
%	O
for	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
>	O
55	O
(	O
chi-square	O
test	I:C0008041
,	O
p<0.001	O
)	O
.	O

The	O
positive	O
biopsy	I:C1514241
rates	O
of	O
Gleason	B:C0332326
7	I:C0332326
or	I:C0332326
above	I:C0332326
prostate	O
cancers	I:C0376358
were	O
2.2	O
%	O
for	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
<	O
35	O
,	O
7.9	O
%	O
for	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
35	O
-	O
55	O
,	O
and	O
36.4	O
%	O
for	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
>	O
55	O
(	O
chi-square	O
test	I:C0008041
,	O
p<0.001	O
)	O
.	O

The	O
positive	O
biopsy	I:C1514241
rates	O
of	O
Gleason	O
7	I:C0332326
or	I:C0332326
above	I:C0332326
prostate	B:C0376358
cancers	I:C0376358
were	O
2.2	O
%	O
for	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
<	O
35	O
,	O
7.9	O
%	O
for	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
35	O
-	O
55	O
,	O
and	O
36.4	O
%	O
for	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
>	O
55	O
(	O
chi-square	O
test	I:C0008041
,	O
p<0.001	O
)	O
.	O

The	O
positive	O
biopsy	I:C1514241
rates	O
of	O
Gleason	O
7	I:C0332326
or	I:C0332326
above	I:C0332326
prostate	O
cancers	I:C0376358
were	O
2.2	O
%	O
for	O
Prostate	B:C4084801
Health	I:C4084801
Index	I:C4084801
<	O
35	O
,	O
7.9	O
%	O
for	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
35	O
-	O
55	O
,	O
and	O
36.4	O
%	O
for	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
>	O
55	O
(	O
chi-square	O
test	I:C0008041
,	O
p<0.001	O
)	O
.	O

The	O
positive	O
biopsy	I:C1514241
rates	O
of	O
Gleason	O
7	I:C0332326
or	I:C0332326
above	I:C0332326
prostate	O
cancers	I:C0376358
were	O
2.2	O
%	O
for	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
<	O
35	O
,	O
7.9	O
%	O
for	O
Prostate	B:C4084801
Health	I:C4084801
Index	I:C4084801
35	O
-	O
55	O
,	O
and	O
36.4	O
%	O
for	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
>	O
55	O
(	O
chi-square	O
test	I:C0008041
,	O
p<0.001	O
)	O
.	O

The	O
positive	O
biopsy	I:C1514241
rates	O
of	O
Gleason	O
7	I:C0332326
or	I:C0332326
above	I:C0332326
prostate	O
cancers	I:C0376358
were	O
2.2	O
%	O
for	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
<	O
35	O
,	O
7.9	O
%	O
for	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
35	O
-	O
55	O
,	O
and	O
36.4	O
%	O
for	O
Prostate	B:C4084801
Health	I:C4084801
Index	I:C4084801
>	O
55	O
(	O
chi-square	O
test	I:C0008041
,	O
p<0.001	O
)	O
.	O

The	O
positive	O
biopsy	I:C1514241
rates	O
of	O
Gleason	O
7	I:C0332326
or	I:C0332326
above	I:C0332326
prostate	O
cancers	I:C0376358
were	O
2.2	O
%	O
for	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
<	O
35	O
,	O
7.9	O
%	O
for	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
35	O
-	O
55	O
,	O
and	O
36.4	O
%	O
for	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
>	O
55	O
(	O
chi-square	B:C0008041
test	I:C0008041
,	O
p<0.001	O
)	O
.	O

By	O
utilizing	O
the	O
Prostate	B:C4084801
Health	I:C4084801
Index	I:C4084801
cutoff	O
of	O
35	O
to	O
men	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
,	O
57.1	O
%	O
(	O
178	O
of	O
312	O
)	O
biopsies	O
could	O
be	O
avoided	O
.	O

By	O
utilizing	O
the	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
cutoff	O
of	O
35	O
to	O
men	B:C0025266
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
,	O
57.1	O
%	O
(	O
178	O
of	O
312	O
)	O
biopsies	O
could	O
be	O
avoided	O
.	O

By	O
utilizing	O
the	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
cutoff	O
of	O
35	O
to	O
men	O
with	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
,	O
57.1	O
%	O
(	O
178	O
of	O
312	O
)	O
biopsies	O
could	O
be	O
avoided	O
.	O

By	O
utilizing	O
the	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
cutoff	O
of	O
35	O
to	O
men	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	B:C1384593
rectal	I:C1384593
examination	I:C1384593
,	O
57.1	O
%	O
(	O
178	O
of	O
312	O
)	O
biopsies	O
could	O
be	O
avoided	O
.	O

By	O
utilizing	O
the	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
cutoff	O
of	O
35	O
to	O
men	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
,	O
57.1	O
%	O
(	O
178	O
of	O
312	O
)	O
biopsies	B:C0005558
could	O
be	O
avoided	O
.	O

Both	O
Prostate	B:C4084801
Health	I:C4084801
Index	I:C4084801
and	O
%	O
p2PSA	I:C3710767
performed	O
well	O
in	O
predicting	O
prostate	O
cancer	I:C0376358
and	O
high	O
grade	I:C0376358
prostate	I:C0376358
cancer	I:C0376358
.	O

Both	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
and	O
%	B:C3710767
p2PSA	I:C3710767
performed	O
well	O
in	O
predicting	O
prostate	O
cancer	I:C0376358
and	O
high	O
grade	I:C0376358
prostate	I:C0376358
cancer	I:C0376358
.	O

Both	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
and	O
%	O
p2PSA	I:C3710767
performed	O
well	O
in	O
predicting	O
prostate	B:C0376358
cancer	I:C0376358
and	O
high	O
grade	I:C0376358
prostate	I:C0376358
cancer	I:C0376358
.	O

Both	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
and	O
%	O
p2PSA	I:C3710767
performed	O
well	O
in	O
predicting	O
prostate	O
cancer	I:C0376358
and	O
high	B:C0376358
grade	I:C0376358
prostate	I:C0376358
cancer	I:C0376358
.	O

The	O
use	O
of	O
Prostate	B:C4084801
Health	I:C4084801
Index	I:C4084801
and	O
%	O
p2PSA	I:C3710767
should	O
be	O
extended	O
to	O
Chinese	O
men	O
with	O
PSA	O
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
.	O

The	O
use	O
of	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
and	O
%	B:C3710767
p2PSA	I:C3710767
should	O
be	O
extended	O
to	O
Chinese	O
men	O
with	O
PSA	O
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
.	O

The	O
use	O
of	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
and	O
%	O
p2PSA	I:C3710767
should	O
be	O
extended	O
to	O
Chinese	B:C0152035
men	O
with	O
PSA	O
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
.	O

The	O
use	O
of	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
and	O
%	O
p2PSA	I:C3710767
should	O
be	O
extended	O
to	O
Chinese	O
men	B:C0025266
with	O
PSA	O
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	O
rectal	I:C1384593
examination	I:C1384593
.	O

The	O
use	O
of	O
Prostate	O
Health	I:C4084801
Index	I:C4084801
and	O
%	O
p2PSA	I:C3710767
should	O
be	O
extended	O
to	O
Chinese	O
men	O
with	O
PSA	O
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	B:C1384593
rectal	I:C1384593
examination	I:C1384593
.	O

